Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,110 GBX | -0.46% | -2.10% | +14.25% |
May. 17 | Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial | RE |
May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
ETFs positioned on AstraZeneca PLC
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.20% | 11 M€ | +0.83% | - | |
5.39% | 200 M€ | +17.40% | ||
5.17% | 17 M€ | +7.73% | - | |
4.89% | 693 M€ | +11.99% | ||
4.11% | 88 M€ | +10.37% | - | |
3.47% | 232 M€ | +12.93% | ||
2.74% | 4 M€ | -.--% | - | |
2.57% | 6 M€ | -.--% | ||
2.53% | 7 M€ | +9.05% | - | |
2.53% | 664 M€ | +11.50% | ||
1.54% | 29 M€ | +8.37% | - | |
1.51% | 2 M€ | -.--% | - | |
1.51% | 2 M€ | +9.19% | - | |
1.26% | 12 M€ | +15.09% | - | |
1.19% | 48 M€ | +9.95% | ||
1.16% | 10 M€ | -3.35% | - | |
0.97% | 7 M€ | +6.58% | - | |
0.89% | 32 M€ | +9.08% | - | |
0.86% | 276 M€ | +11.40% | - | |
0.70% | 264 M€ | -.--% | - | |
0.69% | 187 M€ | +10.81% | - | |
0.69% | 477 M€ | +12.35% | ||
0.57% | 205 M€ | -.--% | ||
0.54% | 284 M€ | -.--% | ||
0.51% | 23 M€ | -.--% | - | |
0.51% | 786 M€ | -.--% | ||
0.50% | 206 M€ | -.--% | ||
0.48% | 727 M€ | +9.36% | ||
0.43% | 283 M€ | +20.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.25% | 239B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B | |
-0.52% | 162B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC